AOD-9604 vs MK-677

Overview

AOD-9604 and MK-677 both relate to growth hormone biology but work through completely different mechanisms. AOD-9604 is a modified fragment of growth hormone (amino acids 176-191) designed to stimulate lipolysis without other GH effects. MK-677 (ibutamoren) is a non-peptide growth hormone secretagogue that stimulates the body’s own GH release. Neither is FDA-approved for body composition enhancement.

This comparison helps understand the difference between direct GH fragment effects and indirect GH stimulation approaches.

Key Facts

Aspect	AOD-9604	MK-677
Type	Peptide (GH fragment)	Non-peptide secretagogue
Structure	16 amino acids	Small molecule
Mechanism	Direct lipolytic	Stimulates GH release
IGF-1 Effect	None (claimed)	Increases IGF-1
FDA Status	Not approved	Not approved
TGA Status	Listed (Australia)	Not approved

Mechanism Comparison

Aspect	AOD-9604	MK-677
Primary Action	Lipolysis	GH secretion
Target	Adipocyte receptors	Ghrelin receptor
GH Increase	No	Yes
IGF-1 Increase	No	Yes
Systemic Effects	Limited (claimed)	Multiple

AOD-9604 Mechanism

1. Selective Lipolysis (Claimed)

   • Derived from GH lipolytic region
   • Targets fat cell receptors
   • Beta-3 adrenergic pathway
   • Fat breakdown without muscle effects

2. Proposed Selectivity

   • No GH-like side effects
   • No blood glucose changes
   • No IGF-1 increase
   • Isolated fat loss mechanism

3. Reality Check

   • Phase 3 trials failed
   • Efficacy unproven for weight loss
   • Current focus on cartilage repair

MK-677 Mechanism

1. Ghrelin Receptor Agonism

   • Mimics ghrelin at pituitary
   • Stimulates GH release
   • Increases GH pulses
   • Maintains elevated GH

2. Growth Hormone Effects

   • Increased GH levels
   • Elevated IGF-1
   • All GH downstream effects
   • Dose-dependent response

3. Metabolic Effects

   • Improved nitrogen balance
   • Increased lean mass (studies)
   • Appetite increase
   • Water retention

Evidence Quality

Factor	AOD-9604	MK-677
Human RCTs	Yes (failed for obesity)	Multiple
GH Increase Data	N/A	Well-documented
Body Composition	Did not meet endpoints	Some evidence
Safety Data	Reasonable	Reasonable
Overall Evidence	Low	Moderate

AOD-9604 Clinical History

Trial	Phase	Outcome
Early studies	1/2	Some promise
Phase 2b obesity	2b	Did not meet primary endpoint
Phase 3 obesity	3	Discontinued for lack of efficacy
Current	N/A	Focus shifted to cartilage

MK-677 Clinical Data

Study	Finding	Quality
GH secretion	Robust increase	Good
Body composition	Modest lean mass increase	Moderate
Elderly studies	Improved sleep, GH	Moderate
Obesity studies	Limited efficacy	Low

Body Composition Effects

AOD-9604

Claim	Trial Evidence
Fat loss	Did not show significant benefit
Selective lipolysis	Unproven in humans
Weight reduction	Failed Phase 3

MK-677

Effect	Evidence
GH increase	Confirmed (2-3x)
IGF-1 increase	Confirmed (~40-100%)
Lean mass	Modest increase in some studies
Fat mass	No significant reduction
Water weight	Increase (GH effect)

Side Effect Profiles

AOD-9604

Effect	Notes
Injection site	Common
Generally mild	In clinical trials
GH effects	Claimed to be absent
Long-term	Unknown

MK-677

Effect	Frequency	Notes
Increased appetite	Very common	Ghrelin effect
Water retention	Common	GH effect
Blood glucose increase	Common	GH effect
Numbness/tingling	Occasional	GH effect
Lethargy	Occasional	Especially initially

Key Safety Difference

Concern	AOD-9604	MK-677
GH side effects	None (claimed)	Yes (expected)
Glucose effects	None reported	Potential increase
Water retention	None reported	Yes
Appetite	None reported	Increased

Administration

Aspect	AOD-9604	MK-677
Route	Subcutaneous	Oral
Convenience	Requires injection	Pill/liquid

Oral Advantage (MK-677)

MK-677 is one of the few GH-related compounds that is orally active, making it significantly more convenient than injectable peptides like AOD-9604.

Regulatory Status

Aspect	AOD-9604	MK-677
FDA	Not approved	Not approved
TGA	Listed (OTC Australia)	Not approved
WADA	Prohibited	Prohibited
US Status	Research chemical	Research chemical

Research Applications

AOD-9604 Current Focus

Area	Status
Weight loss	Abandoned (failed trials)
Cartilage repair	Active research
Osteoarthritis	Being studied

MK-677 Research Areas

Area	Status
GH deficiency	Studied
Sarcopenia	Studied
Sleep quality	Some data
Anti-aging research	Interest

Cost and Availability

Factor	AOD-9604	MK-677
Research chemical	Available	Available
Relative cost	Moderate	Lower
Quality variation	Significant	Significant
Oral option	No	Yes

Comparison to Alternatives

vs Actual GH

Factor	AOD-9604	MK-677	HGH
GH increase	No	Indirect	Direct
IGF-1 increase	No	Yes	Yes
Fat loss	Unproven	Minimal	Some
Muscle	No	Some	Yes
Cost	Moderate	Low	High
Legal	Research	Research	Rx only

vs GLP-1 Drugs for Weight Loss

Factor	AOD-9604	MK-677	Semaglutide
Weight loss	Failed trials	Minimal	15-17%
Evidence Level	Low	Moderate	Very high
FDA approved	No	No	Yes

Summary

Factor	AOD-9604	MK-677
Type	Peptide fragment	Small molecule
Mechanism	Lipolysis (claimed)	GH secretion
GH Effects	None (claimed)	Full GH effects
Route	Injection	Oral
Evidence for Fat Loss	Failed trials	Minimal
Clinical History	Phase 3 failed	Multiple studies
Main Effects	Uncertain	GH/IGF-1 increase

Key Takeaways

1. Different mechanisms: AOD-9604 is GH fragment; MK-677 stimulates GH release
2. MK-677 has GH effects: Including side effects like appetite increase, glucose effects
3. AOD-9604 failed for obesity: Phase 3 trials discontinued
4. MK-677 is oral: Convenient vs injectable AOD-9604
5. Neither proven for weight loss: Both inferior to GLP-1 drugs
6. MK-677 increases GH/IGF-1: Well-documented; AOD-9604 claims no increase
7. Different side effect profiles: MK-677 has GH-related effects; AOD-9604 claims none
8. Both are research chemicals: Neither approved for body composition enhancement

---

This comparison is for educational purposes only. Neither compound is FDA-approved for weight loss or body composition. Both are prohibited by WADA. Discuss with a healthcare provider.